CJC-1295 with DAC Side Effects & Safety Phase 1 data described CJC-1295 with DAC as relatively well tolerated at lower dose ranges, with adverse events increasing at higher exposure
clone 3A1
10b) in both wild type and Tet2 knock out G1E-ER4 cells

Disclosures: Dimple Desai: Nothing to Disclose, Rashmee Patil: Akero Therapeutics: Grant/Research Support, Altimmune: Grant/Research Support, 89Bio: Grant/Research Support, Boehringer Ingelheim: Grant/Research Support, Boston Pharmaceuticals: Grant/Research Support, Eli Lilly: Grant/Research Support, Helio Health: Grant/Research Support, Inventiva: Grant/Research Support, Madrigal Pharmaceuticals: Grant/Research Support, Madrigal Pharmaceuticals: Speaking and Teaching, Merck: Grant/Research Support, Novo Nordisk: Grant/Research Support, Novo Nordisk: Consultant, Galectin Therapeutics: Grant/Research Support, Hepion Pharmaceuticals: Grant/Research Support, GlaxoSmithKline: Grant/Research Support, Corcept Therapeutics: Grant/Research Support 1067 THE EFFECT OF DIET COMPOSITION EXPOSOME ON THE NATURAL HISTORY OF METABOLIC-ASSOCIATED STEATOTIC LIVER DISEASE IN THE MILLION VETERAN PROGRAM COHORT Lauren Callans 1 David Kaplan 2 Kerry Ivey 3 Kyong-Mi Chang 4 , 1 Perelman School of Medicine, University of Pennsylvania, 2 Perelman School of Medicine, 3 Harvard Medical School, 4 Corporal Michael J
